The use of radionuclide therapy through therapeutic radionuclides showed positive results for clinical applications such as iodine-131 (131I) for thyroid carcinoma, [131I]MIBG for malignant and metastatic pheochromocytoma, yttrium-90 (90Y) anti CD20 immunoglobulin for metastatic neuroendocrine tumors, and [177Lu]Lu-PSMA for prostate cancer therapy with high PSMA expression 24. Here, FOLH1 is linked to prostate carcinoma.